➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKesson
AstraZeneca
Johnson and Johnson
McKinsey
Baxter

Last Updated: October 17, 2021

DrugPatentWatch Database Preview

Pemigatinib - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic sources for pemigatinib and what is the scope of freedom to operate?

Pemigatinib is the generic ingredient in one branded drug marketed by Incyte Corp and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pemigatinib has eighty-seven patent family members in thirty-four countries.

One supplier is listed for this compound.

Summary for pemigatinib
International Patents:87
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 17
Clinical Trials: 16
Patent Applications: 35
What excipients (inactive ingredients) are in pemigatinib?pemigatinib excipients list
DailyMed Link:pemigatinib at DailyMed
Recent Clinical Trials for pemigatinib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The Fourth Affiliated Hospital of Zhejiang University School of MedicinePhase 2
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 2
Oregon Health and Science UniversityPhase 1

See all pemigatinib clinical trials

US Patents and Regulatory Information for pemigatinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Incyte Corp PEMAZYRE pemigatinib TABLET;ORAL 213736-001 Apr 17, 2020 RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Incyte Corp PEMAZYRE pemigatinib TABLET;ORAL 213736-001 Apr 17, 2020 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Incyte Corp PEMAZYRE pemigatinib TABLET;ORAL 213736-002 Apr 17, 2020 RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Incyte Corp PEMAZYRE pemigatinib TABLET;ORAL 213736-002 Apr 17, 2020 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Incyte Corp PEMAZYRE pemigatinib TABLET;ORAL 213736-002 Apr 17, 2020 RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Incyte Corp PEMAZYRE pemigatinib TABLET;ORAL 213736-001 Apr 17, 2020 RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for pemigatinib

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2861595 301131 Netherlands ⤷  Try it Free PRODUCT NAME: PEMIGATINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/21/1535 20210329
2861595 PA2021519 Lithuania ⤷  Try it Free PRODUCT NAME: PEMIGATINIBAS ARBA JO FARMACISKAI PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/21/1535 20210326
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
AstraZeneca
Johnson and Johnson
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.